News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
GlaxoSmithKline (JOBS) Says US Still Reviewing Clot Disorder Drug
September 22, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Sept 19 (Reuters) - U.S. health officials still are reviewing GlaxoSmithKline Plc's proposed clotting disorder drug Promacta, the company said on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
GSK
MORE ON THIS TOPIC
Approvals
AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancer
September 8, 2026
·
2 min read
·
Tristan Manalac
Insights
Can Benelux turn scientific strength into larger biotech scale?
September 8, 2026
·
4 min read
·
Jennifer C. Smith-Parker
FDA
Replimune’s melanoma drug would have been rejected again if not for senior CBER official
September 3, 2026
·
2 min read
·
Tristan Manalac
Insights
Breaking borders: Building biotech scale in Benelux
September 3, 2026
·
1 min read
·
Jennifer C. Smith-Parker
